FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss...

24
FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine

TAGS:

Transcript of FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss...

Page 1: FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.

FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease?

Alan C. Moss MD, FEBG, FACG, AGAF

Associate Professor of Medicine

Page 2: FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.

Typical Pre-Clinical Steps in Development

Page 3: FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.

Elements of Clinical Trial Design in IBD

1. Patient Selection

2. Intervention

3. Outcomes

Page 4: FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.

Patient Selection

Page 5: FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.

Populations in Prior FMT Trials in IBD

StudyDuration of

DiseaseDisease Activity

Current Meds

Vaughn 2014 14 yrs 10 (HBI) Steroids, AZA/6MP

Moayyedi 2014 ? >4 (Mayo) Steroids, AZA/6MP, Anti-TNF

Kunde S 2013 1-7 yrs 30-55 (PUCAI)

5-ASA, 6MP, Steroids

Kump P 2013 2-12 yrs 8-11 (Mayo) Steroids, Anti-TNF, 5-ASA

Angelberger S 2013 2-10 yrs 8-11 (Mayo) 5-ASA, Probiotics

Page 6: FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.

“Ideal” Populations to Study

1. Early after diagnosis, prior to immunosuppresive therapy

2. Early after Crohn’s resection to prevent endoscopic recurrence

3. Genotype-specific

4. Patients in remission to reduce risk of relapse

5. Proctitis (UC) – mode of administration

6. Pouchitis (UC)

7. Active ileal Crohn’s - ?more dysbiosis driven

Page 7: FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.

Rationale for Earlier Intervention - Window of Inflammation

0

2400 12 24 36 48 60 72 84 96 108 120 132 144 156 168 180 192 204 216 228

100

90

80

70

60

50

40

30

20

10

Penetrating

Stricturing

Cu

mu

lati

ve P

rob

abili

ty (

%)

Inflammatory

Months

Cosnes J, et al. Inflamm Bowel Dis. 2002;8:244-250.

Page 8: FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.

Rational for Early Intervention - Dysbiosis is Established Early

Gevers D et al Cell Host Microbe. 2014 Mar 12;15(3):382-92

Page 9: FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.

Rationale for Genotype Enrichment

Frank DN, Inflamm Bowel Dis. 2011 Jan;17(1):179-84

Page 10: FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.

Who to Exclude

• Food allergies• Pregnant• Cancer• Immunocompromised• Cirrhosis• History of valvular heart disease

Page 11: FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.

Variables to Control for in Enrolled Population

Sommer F, Nat Rev Microbiol. 2013 Apr;11(4):227-38

Page 12: FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.

Interventions

Page 13: FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.

Variables to Consider for Intervention

1. Dose 2. Delivery 3. Duration

• Stool weight• Solution

concentration• Microbial

consituents• Aerobe / Anerobic

prep

• Naso-jejnual• Enema• Colonoscopy• Capsule• Fresh / Frozen

• Loading & Maintenance

• Frequency of administration

Page 14: FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.

Scenarios for Intervention – Parallel Design

Study Population Randomize

100g Freeze-Thaw FMT

Sham FMT

50g Freeze-Thaw FMT

Study Population Randomize

100g Fresh FMT

Probiotics

100g Freeze-Thaw FMT

Page 15: FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.

Scenarios for Intervention – Cross-Over

Randomize

100g Freeze-Thaw FMT

Sham FMT 100g Freeze-Thaw FMT

Sham FMT

Page 16: FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.

Solutions to Uncertainties in Intervention

1. Tailor administration to site of inflammation

2. Standard concentration (fecal slurry by donor weight and re-constitution solution)

3. Frozen pre-screened aliquots

4. Regular administration - colonization alone does not guarantee efficacy

Page 17: FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.

Carroll I, PLoS One. 2012; 7(10): e46953

Frozen Donor Stool Retains its Diversity

Page 18: FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.

Baseli

ne

FM

T

Week

1

Week 2

Week 4

Week

8

Week 1

2

Week 2

40

5

10

15

20

R1001

R1002

R1003

R1004

R1005

R1006

R1007

R1008

R1009

R101 1

R1012

HB

I

Single FMT Not Sufficient – Data in Crohn’s

Vaughn B, DDW 2014

Page 19: FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.

Outcomes

Page 20: FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.

Clinical Efficacy Outcomes

1. Measure of Response / Remission

- endoscopic measure important

- Patient Reported Outcomes (PROs)

- CDAI, SCCAI no longer convincing alone

- Quality of Life

2. Timing of Outcome Assessment

- 4 & 8 weeks for response

- week 8 and 26 for remission (endoscopic)

Page 21: FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.

Safety

• Reporting of Adverse Events has been inadequate to date

• Use of industry-standards for attribution and severity important

• Long-term surveillance critical (storage of archival donor samples for testing)

Page 22: FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.

Physiological Outcomes

• Paired diversity assessments (pre- & post-)• Metabolomics• Inflammatory markers – CRP, Fecal Calprotectin• T-cell phenotypes

Page 23: FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.

04

12 24Weeks

FMT

8

Microbiome

Sequencing

PB T-cell phenotypes

LP T-cell phenotypes

Clinical / Safety Assessment

“Impact of Fecal Biotherapy (FBT) on Microbial Diversity in Patients Inflammatory Bowel Disease”

ClinicalTrials.gov Identifier:NCT01847170

Page 24: FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.

Conclusions

• FMT should be studied in similar manner to drug therapy to test its efficacy & safety

- risk:benefit, cost-effectiveness

• Challenges – regulatory, funding, standardization

• Initial promise tempered by variable open-label study outcomes

• Need for tailored intervention in targeted sub-groups of patients with IBD


Spectrum of Gluten and Wheat Related Disorders Sheila E. Crowe, MD, FRCPC, FACP, FACG, AGAF Department of Medicine University of California, San Diego.

Spectrum of Gluten and Wheat Related Disorders Sheila E. Crowe, MD, FRCPC, FACP, FACG, AGAF Department of Medicine University of California, San Diego.

Douglas G. Adler MD, FACG, AGAF, FASGE, Series Editor … · 2019. 7. 31. · Adenoma and Defining the Margins for Resection To improve visualization of adenomas in the duodenum,

Douglas G. Adler MD, FACG, AGAF, FASGE, Series Editor … · 2019. 7. 31. · Adenoma and Defining the Margins for Resection To improve visualization of adenomas in the duodenum,

MD. MHS. FACP. FACG. FASGE. AGAF. President Anniston …alagastro.org/wp-content/uploads/Elougeidi_Mohamad_CV.pdf · 2018-03-08 · September 2015 Eloubeidi MA B .1 Mohamad A. Eloubeidi

MD. MHS. FACP. FACG. FASGE. AGAF. President Anniston …alagastro.org/wp-content/uploads/Elougeidi_Mohamad_CV.pdf · 2018-03-08 · September 2015 Eloubeidi MA B .1 Mohamad A. Eloubeidi

Director of Hepatology Advances in Hepatology · 2019. 8. 14. · Advances in Hepatology Luis S. Marsano, MD, FAASLD, FACG, AGAF, FASGE Professor of Medicine, Director of Hepatology

Director of Hepatology Advances in Hepatology · 2019. 8. 14. · Advances in Hepatology Luis S. Marsano, MD, FAASLD, FACG, AGAF, FASGE Professor of Medicine, Director of Hepatology

The Keys to Work-Life Balance Amy S. Oxentenko, MD, FACP, FACG, AGAF Mayo Clinic, Rochester.

The Keys to Work-Life Balance Amy S. Oxentenko, MD, FACP, FACG, AGAF Mayo Clinic, Rochester.

Rad Agrawal MD FACP FACG AGAF FASGE A … · A Review of the Pathogenesis, Management and Complications of ... A Review of the Pathogenesis, Management and Complications of Portal

Rad Agrawal MD FACP FACG AGAF FASGE A … · A Review of the Pathogenesis, Management and Complications of ... A Review of the Pathogenesis, Management and Complications of Portal

Knowledge-power-Action - ImedexKnowledge-power-Action April 4 2009 Rosemont illinois DonalD e. stephens convention centeR course director russell d. cohen, md, fAcg, AgAf University

Knowledge-power-Action - ImedexKnowledge-power-Action April 4 2009 Rosemont illinois DonalD e. stephens convention centeR course director russell d. cohen, md, fAcg, AgAf University

BIOGRAPHY - ego-summit.comego-summit.com/CVs/PROF_Tarek_CV.pdfProf. Tarek Hassanein M.D, FACP, FACG, AGAF, FAASLD Professor of Medicine, UCSD School of Medicine. Director of Outreach

BIOGRAPHY - ego-summit.comego-summit.com/CVs/PROF_Tarek_CV.pdfProf. Tarek Hassanein M.D, FACP, FACG, AGAF, FAASLD Professor of Medicine, UCSD School of Medicine. Director of Outreach

Douglas G. Adler MD, FACG, AGAF, FASGE, Series Editor ... · procedures as well as endoscopic drainage. Waiting until at least four weeks after the onset of symptoms allows fluid

Douglas G. Adler MD, FACG, AGAF, FASGE, Series Editor ... · procedures as well as endoscopic drainage. Waiting until at least four weeks after the onset of symptoms allows fluid

Antithrombotics and Endoscopy: Advice for Endoscopy Nurses from Cardiogastroenterology Clinic Neena S. Abraham MD, MSc (EPID), FACG, FASGE, AGAF Professor.

Antithrombotics and Endoscopy: Advice for Endoscopy Nurses from Cardiogastroenterology Clinic Neena S. Abraham MD, MSc (EPID), FACG, FASGE, AGAF Professor.

Therapeutic Targets for NASH in HIV - Paris Nash … Targets for NASH in HIV Unique opportunities and challenges Richard K. Sterling, MD, MSc, FACP, FACG, AGAF, FAASLD VCU Professor

Therapeutic Targets for NASH in HIV - Paris Nash … Targets for NASH in HIV Unique opportunities and challenges Richard K. Sterling, MD, MSc, FACP, FACG, AGAF, FAASLD VCU Professor

Douglas G. Adler MD FACG AGAF FASGE Series Editor ... · Barrett’s esophagus (BE), first described in 1950 by Dr. Norman Barrett, a British thoracic surgeon, refers to replacement

Douglas G. Adler MD FACG AGAF FASGE Series Editor ... · Barrett’s esophagus (BE), first described in 1950 by Dr. Norman Barrett, a British thoracic surgeon, refers to replacement

Colon Prep Update: 2015 Let’s be clear Harish K Gagneja, MD, AGAF, FACG, FASGE President, TSGE President, Austin Gastroenterology, P.A. .

Colon Prep Update: 2015 Let’s be clear Harish K Gagneja, MD, AGAF, FACG, FASGE President, TSGE President, Austin Gastroenterology, P.A. .

Colorectal Cancer The Preventable Killer...Dennis J. Ahnen MD, AGAF, FACGDennis J. Ahnen MD, AGAF, FACG Colorectal Cancer The Preventable Killer Relevant Conflicts of Interest Co-Investigator

Colorectal Cancer The Preventable Killer...Dennis J. Ahnen MD, AGAF, FACGDennis J. Ahnen MD, AGAF, FACG Colorectal Cancer The Preventable Killer Relevant Conflicts of Interest Co-Investigator

High Value Care of GI Bleeding Bennie R. Upchurch MD, FACP, FASGE, AGAF, FACG Medical Director, GI Bleeding Program, Division of Gastroenterology, Nutrition,

High Value Care of GI Bleeding Bennie R. Upchurch MD, FACP, FASGE, AGAF, FACG Medical Director, GI Bleeding Program, Division of Gastroenterology, Nutrition,

JOSE M. NIETO - gastroenterologoscr.comgastroenterologoscr.com/wp-content/uploads/2019/09/JOSE...CURRICULUM VITAE JOSE M. NIETO, DO AGAF FACP FACG FASGE Board Certified in Internal

JOSE M. NIETO - gastroenterologoscr.comgastroenterologoscr.com/wp-content/uploads/2019/09/JOSE...CURRICULUM VITAE JOSE M. NIETO, DO AGAF FACP FACG FASGE Board Certified in Internal

Viral Hepatitis C: The Final Countdownginurse.com/Library/CourseMaterial/Saab_Hepatitis C...The Final Countdown Sammy Saab, MD, MPH, AGAF, FACG, FAASLD Professor of Medicine and Surgery

Viral Hepatitis C: The Final Countdownginurse.com/Library/CourseMaterial/Saab_Hepatitis C...The Final Countdown Sammy Saab, MD, MPH, AGAF, FACG, FAASLD Professor of Medicine and Surgery

GERD Management Mgmt... · 2020-03-18 · GERD Management David Armstrong MA, MB BChir, FRCPC, FRCP(UK), CAGF, FACG, AGAF. McMaster University. Adriana Lazarescu MD, FRCPC . University

GERD Management Mgmt... · 2020-03-18 · GERD Management David Armstrong MA, MB BChir, FRCPC, FRCP(UK), CAGF, FACG, AGAF. McMaster University. Adriana Lazarescu MD, FRCPC . University

Nimish Vakil, MD, FACP, FACG, AGAF, FASGE Clinical Adjunct ... · Prevalence and Burden 35 million adults suffer from CIC 13 million people suffer with IBS-C These conditions are

Nimish Vakil, MD, FACP, FACG, AGAF, FASGE Clinical Adjunct ... · Prevalence and Burden 35 million adults suffer from CIC 13 million people suffer with IBS-C These conditions are

Parenteral Nutrition Designing the Solution Mark H. DeLegge, MD, FACG, AGAF, FASGE Digestive Disease Center Medical University of South Carolina.

Parenteral Nutrition Designing the Solution Mark H. DeLegge, MD, FACG, AGAF, FASGE Digestive Disease Center Medical University of South Carolina.